Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc

Hacettepe University

Status: Enrolling

Conditions: Glucocorticoids Toxicity; Vasculitis; Systemic Lupus Erythematosus; Rheumatoid Arthritis

Study type: Observational

Funder types: Other

Identifiers

NCT05292456

KA- 21026

Details and patient eligibility

About

Hypothesis 1: A reduction in side effects is achieved with monitoring glucocorticoid treatment by using the Glucocorticoid Toxicity Index (GTI) in patients using glucocorticoids.

Hypothesis 2: Monitoring treatment by using GTI in patients using glucocorticoids causes a decrease in glucocorticoid toxicity and an increase in the quality of life of patients.

Hypothesis 3: With the involvement of the clinical pharmacist in the multidisciplinary team in patients using glucocorticoids, the drug-related problems of the patients are detected and prevented.

The aim of this study was to evaluate the glucocorticoid treatment of patients with RA, SLE and vasculitis treated with glucocorticoids prospectively by a multidisciplinary team with GTI. In addition, it was aimed to identify and prevent drug-related problems by reviewing all drugs used in these patients by the clinical pharmacist.

Full description

In this study, the side effects of glucocorticoids used by patients will be evaluated using the Glucocorticoid Toxicity Index (GTI) index. This index includes areas for commonly recognized adverse events as a result of cumulative steroid exposure. It is weighted and measures both worsening and improvement. Scores range from -346 to 439 with cumulative worsening score relating to an increase in GC toxicity burden. "-" points indicate improvement, "+" points indicate worsening. The higher the patient's burden of glucocorticoid toxicity, the higher his score.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years and over
• Individuals who have received glucocorticoid treatment for RA, SLE or vasculitis in the last 2 years or at current admission.
• Patients approved by the physician to participate in the study
• Patients giving written consent

Exclusion criteria

• Younger than 18
• Patients with communication disabilities
• Patients involved in another clinical and/or drug trial

Trial design

200 participants in 2 patient groups

RA, SLE, and vasculitis patients who have just started glucocorticoid treatment

RA, SLE and vasculitis patients receiving glucocorticoid treatment for the last 2 years